Visiongain has launched a new pharma report Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others.
LONDON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth.
For sample pages of this timely report please click on: https://www.visiongain.com/report/dermatological-drugs-market-forecast-2018-2028/
The lead analyst of the report commented, “Visiongain notes that strong growth is expected in the skin structure infections (SSSI) sector of the dermatological drugs market. The increasing number of immunocompromised patients and the ageing population will contribute to the expansion expected in the segment of the market. We also expect growth to be driven by the development of new antibacterial drugs with better safety and efficacy profiles than existing antibiotics.”
To request your free report overview please email sara.peerun@visiongain.com or call +44 207 3366100.
Leading companies featured in the report include AbbVie, Amgen, Bayer AG, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK), Johnson & Johnson, LEO Pharma, Merck & Co, Inc., Novartis, Pfizer.
To read full TOC please click on: https://www.visiongain.com/report/dermatological-drugs-market-forecast-2018-2028/